IP Verse

Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma - EP3463457B1

PatentPatent Analysis

EP3463457

BRISTOL MYERS SQUIBB
Application Number
EP17730627A
Filing Date
Jun 1, 2017
Status
Granted And Under Opposition
May 26, 2023
Grant Date
Jun 28, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3781132B1
EP3818078B1
EP3631454B1

Bibliography

The patent EP3463457B1 was granted to Bristol Myers Squibb on Jun 28, 2023 following the initial filing on Jun 1, 2017 under the application number EP17730627A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

PAJAROMar 27, 2024ADMISSIBLE
STRAWMANMar 22, 2024ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents